Arden Trust’s Aimmune Therapeutics AIMT Stock Holding History

Arden Trust’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,831	Closed	-$113K	–	820
2020 Q1	$113K	Buy	+7,831	New	+$200K	0.02%	366

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Arden Trust's AIMT Position: Q2 2020 in Review

Arden Trust sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 7,831 shares — an estimated $113K sold.

Arden Trust first reported a position in AIMT in Q1 2020 and held it in 1 quarter. The position peaked at $113K in Q1 2020. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

Arden Trust reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
Arden Trust sold 7,831 Aimmune Therapeutics shares in Q2 2020, an estimated $113K.
Arden Trust first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 1 quarter.
Arden Trust's Aimmune Therapeutics position peaked at $113K in Q1 2020.
165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Arden Trust's 13F filing for Q2 2020, filed 9 Jul 2020.